[{"orgOrder":0,"company":"Unnatural Products","sponsor":"BridgeBio Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Agreement","leadProduct":"Macrocyclic Peptide","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Unnatural Products","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Unnatural Products \/ BridgeBio Pharma","highestDevelopmentStatusID":"3","companyTruncated":"Unnatural Products \/ BridgeBio Pharma"},{"orgOrder":0,"company":"Unnatural Products","sponsor":"Argenx","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Peptide","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Unnatural Products","amount2":1.5,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":1.5,"dosageForm":"Oral","sponsorNew":"Unnatural Products \/ Argenx","highestDevelopmentStatusID":"3","companyTruncated":"Unnatural Products \/ Argenx"}]

Find Clinical Drug Pipeline Developments & Deals by Unnatural Products

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Vietnam Medi-Pharm Expo
                          Not Confirmed
                          Vietnam Medi-Pharm Expo
                          Not Confirmed

                          Details : The collaboration aims to discover and develop oral macrocyclic peptide drugs targeting traditionally “undruggable,” disease targets, using UNP’s proprietary drug discovery platform.

                          Product Name : Undisclosed

                          Product Type : Peptide

                          Upfront Cash : Undisclosed

                          July 01, 2025

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Technology

                          Highest Development Status : Discovery Platform

                          Sponsor : Argenx

                          Deal Size : $1,500.0 million

                          Deal Type : Collaboration

                          blank

                          02

                          Vietnam Medi-Pharm Expo
                          Not Confirmed
                          Vietnam Medi-Pharm Expo
                          Not Confirmed

                          Details : Under the terms of the agreement, UNP assumed responsibility for R&D, and BridgeBio will assume the further development of the macrocyclic peptide candidates for rare diseases and oncology.

                          Product Name : Undisclosed

                          Product Type : Peptide

                          Upfront Cash : Undisclosed

                          March 12, 2024

                          Lead Product(s) : Macrocyclic Peptide

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery Platform

                          Sponsor : BridgeBio Pharma

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank